Alnylam Pharmaceuticals Inc. Q2 Loss Decreases, but misses estimates

(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) revealed Loss for its second quarter that increased from the same period last year and missed the Street estimates.

The company's bottom line totaled -$277.40 million, or -$2.29 per share. This compares with -$189.56 million, or -$1.61 per share, in last year's second quarter.

Excluding items, Alnylam Pharmaceuticals Inc. reported adjusted earnings of -$245.83 million or -$2.03 per share for the period.

Analysts on average had expected the company to earn -$1.63 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 1.9% to $224.82 million from $220.55 million last year.

Alnylam Pharmaceuticals Inc. earnings at a glance (GAAP) :

-Earnings (Q2): -$277.40 Mln. vs. -$189.56 Mln. last year. -EPS (Q2): -$2.29 vs. -$1.61 last year. -Analyst Estimate: -$1.63 -Revenue (Q2): $224.82 Mln vs. $220.55 Mln last year.

-Guidance: Full year revenue guidance: $870 - $930 Mln